PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Bromocriptine”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,153 records · Page 64Linked to original sources

Effects of long-term treatment with bromocriptine on pituitary prolactinoma in a male.

Poor surgical results are obtained when operating on large prolactinomas, especially when an extrasellar growth is demonstrated. Several groups have reported tumor regression following bromocriptine treatment. A case report is presented of a young hyperprolactinemic man with a large pituitary adenoma with suprasellar extension, normal visual fields, decreased libido, impotence, hypogonadism and azoospermia. This man was treated with high doses of bromocriptine for a period of 5 months. A significant improvement of potency libido and sperm concentration associated with radiological evidence of a marked reduction of tumor size was noted following suppressive treatment with this ergot alkaloid.

Adult↗

Excitation by dopamine D-2 receptor agonists, bromocriptine and LY 171555, in caudate nucleus neurons activated by nigral stimulation.

Electrophysiological studies using cats anesthetized with alpha-chloralose were carried out to determine whether or not the dopamine D-2 receptor mediates the excitation of the caudate nucleus (CN) neurons activated by stimulation of the substantia nigra (SN). Microiontophoretic application of domperidone (D-2 antagonist) produced a significant inhibition of spikes elicited by SN stimulation in 20 of 27 CN neurons. When bromocriptine and LY 171555 (D-2 agonists) were iontophoretically applied to the CN neurons in which the SN-induced spikes were inhibited by domperidone, an increase in spontaneous firing rate was observed in 18 of 20 neurons and all of 10 neurons tested, respectively. However, no alterations of firing occurred with bromocriptine or LY 171555 in any 7 neurons in which the SN-induced spikes were not affected by domperidone. The increase in firing rate by the D-2 agonists was apparently antagonized during simultaneous application of domperidone and haloperidol, but not affected during application of SCH 23390 (D-1 antagonist). These results strongly suggest that the spike generation of the CN neurons upon SN stimulation is mediated by the dopamine D-2 receptor.

Animals↗

Chronic treatment with bromocriptine induces behavioral supersensitivity in rats.

Chronic treatment of rotating rats with equipotent doses of the dopamine (DA) agonists apomorphine (APO), 3-(3,4-dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide (DPPP) and bromocriptine (BRO) for four weeks resulted in marked differences in rotational activity following acute administration of these agonists. Whereas chronic treatment with APO and DPPP failed to produce any significant changes in agonist-induced rotational behavior, chronic BRO treatment induced a progressive increase in rotational activity up to a mean 200% increase over controls at four weeks. These findings may, in part, explain the long-term clinical efficacy of bromocriptine in patients with Parkinson's disease.

Animals↗

Hormone patterns during bromocriptine-induced pregnancy in hyperprolactinemic patients.

Plasma prolactin (PRL) and human placental lactogen (HPL), and urinary estriol and pregnanediol were studied during pregnancies induced with bromocriptine (Parlodel, Sandoz) in 10 cases of hyperprolactinemia. Previous selective adenomectomy or intrasellar implantation of radioactive gold (198Au) failed to induce a complete remission in 3 of these subjects. PRL rapidly increases after bromocriptine withdrawal, reaching values higher than those in normal women in the same stage of pregnancy within a few weeks. At term, pathological PRL levels occurred in 3 subjects only (with distinct alterations of the sella turcica). Estriol, pregnanediol and HPL were normal in all cases. These findings suggest that PRL levels higher than those normally observed during pregnancy do not alter fetoplacental endocrine function.

Adult↗

Effects of prolactin and bromocriptine on the luteal phase in infertile women.

Infertile women with regular periods but with shortened luteal phases were found to have higher mean levels of serum prolactin and lower serum progesterone levels in the midluteal phase than women with apparently normal ovarian function (P less than 0.001). Serum estrogens and gonadotropins did not differ from the reference group but the ratio FSH/LH was reduced in the midluteal phase (P less than 0.05). LHRH-loading test in the midfollicular phase also resulted in a lower ratio of FSH/LH (P less than 0.05). Thirty-six infertile women with short luteal phases were treated with bromocriptine in a double-blind fashion. The drug moderately reduced the length of the cycle (P less than 0.01). The hyperthermia of the luteal phase was measured planimetrically. Both the total area and the area per day of the luteal phase were significantly increased during the cycles of active treatment (P less than 0.02 and 0.05, respectively). Prolactin was depressed by the drug. After cessation of therapy a very significant rebound elevation of prolactin for at least 2 wk was noted. Bromocriptine therapy further reduced FSH levels at midcycle. Estrogens were elevated during the midluteal phase whereas progesterone was not affected by the treatment. Seven conceptions occurred during the study, six of which during placebo treatment. The conception cycles were characterized by significantly higher levels of progesterone and estrogens during the luteal phase as opposed to the infertile cycles. Four of the pregnancies terminated in spontaneous abortion. The endocrine data of these conception cycles did not differ from those of the successful ones.

Adult↗

Comparison of four different dosages of injectable bromocriptine retard for puerperal ablactation.

The clinical efficacy, tolerance and effect on plasma prolactin levels of four different dosages of intramuscular bromocriptine retard were compared. 108 Chinese puerperas with a mean body weight of 58 kg, who chose not to breast-feed following vaginal delivery, were randomized into four equal groups. The patients in each group were given intramuscular bromocriptine retard: 20, 30, 40 or 50 mg. The injection was well tolerated by all, except for two patients who developed small haematomas at the site of the injection and 2 patients who complained of dizziness. Ablactation occurred in 100% of the patients in the 40 mg group, but was successful in only 92 and 91% of the patients in the 20 and 30 mg groups, respectively. There were two cases of suboptimal response in the 50 mg group, despite marked reduction in plasma prolactin levels. Both these patients had developed moderate breast engorgement before they received the injection. The difference in response among the four groups was not statistically significant. We recommend that the injection be given prior to the development of breast engorgement.

Body Weight↗

Depression of the monosynaptic reflex by apomorphine or bromocriptine is not mediated by D1/D2 receptors.

The role of dopamine in spinal motor transmission was investigated using spinal reflexes in acutely spinalized rats. Intravenous administration of a relatively high dose of the dopamine receptor agonist apomorphine-HCl (3 mg/kg) or the D2 receptor agonist bromocriptine mesylate (1 mg/kg) reduced the amplitude of the monosynaptic reflex (MSR). Depression of the MSR by both drugs was antagonized by haloperidol (1 mg/kg), but not by the D2 receptor antagonists YM-09151-2 (0.2 mg/kg) and sulpiride (10 mg/kg), or by a combination of the D1 receptor antagonist SKF 83566 (0.01 mg/kg) and sulpiride (10 mg/kg). Intravenous administration of the selective D1 receptor agonist SKF 77434 (0.1 and 1 mg/kg) and the D2/D3 receptor agonist quinpirole-HCl (0.1 and 1 mg/kg) had no significant effect on the MSR. Simultaneous administration of SKF 77434 and quinpirole had no significant effect on the MSR. These results show that stimulation of D1/D2 receptors has little influence on the MSR, and suggest that descending dopaminergic systems mediating these receptors have little influence on MSR transmission. Apomorphine and bromocriptine may inhibit the MSR via other subtypes of D1/D2 or other, as yet undiscovered, dopamine receptors or via non-dopaminergic mechanisms.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗

Further acquisitions on gonadal function in bromocriptine treated hyperprolactinemic male patients.

The diurnal variation of plasma total and free testosterone (tT and fT) and the gonadotropinemic response to LH-RH were evaluated in a group of hyperprolactinemic impotent males with pituitary microprolactinoma before and during therapy with bromocriptine, a well known dopamine agonist drug. Before treatment, basal levels not only of tT but also of fT were decreased and the diurnal variation of both tT and fT was absent. Moreover, the LH-RH test showed a delay in the LH response peak, together with normal basal levels of LH. Bromocriptine therapy caused normalization of both the secretion response of LH to LH-RH and of the secretion pattern of tT and of fT (basal levels and diurnal variation) besides a significant decrease in PRL levels and an improvement in sexual function. The possible effects of high plasma levels of PRL at various levels of the hypothalamus-pituitary-testicular axis are discussed.

Adult↗

T-cell dysregulation in patients with hyperprolactinemia: effect of bromocriptine treatment.

We studied four patients with tumoral hyperprolactinemia and normal ovarian function before and after prolactine levels had become normal with treatment with bromocriptine (BrC), a dopamine agonist that inhibits prolactin release. Their proliferative responses to concanavalin A, pokeweed mitogen, and, to a lesser extent, phytohemagglutinin, their spontaneous and concanavalin A-induced suppression, and their production of interleukin 2 were found to be decreased and to correct partially or completely after bromocriptine treatment. The T-cell response to interleukin 2 was low in two patients in whom it increased after BrC treatment. These findings give insight on the immunomodulatory role of prolactin in vivo.

Adult↗

Immunohistochemical, electron microscopic, and morphometric studies of human prolactinomas after short-term bromocriptine treatment.

Two cases of human prolactinomas after short-term treatment with bromocriptine were studied by means of immunohistochemistry for prolactin, electron microscopy, and morphometry at the ultrastructural level. The results obtained showed an abundance of immunoreactive secretory granules in the tumor cells, a paucity in the electron microscopic images suggesting exocytosis of secretory granules, and no significant changes in the volume density of rough endoplasmic reticulum when compared with untreated (control) tumor cells. These findings strongly suggest that the effects of short-term bromocriptine treatment for lowering serum prolactin levels did not inhibit protein and secretory granule synthesis but rather caused a disturbance in the secretion of prolactin granules. The present morphometrical data suggest the possibility that a reduction in the number of cytoplasmic microtubules might be related to the disturbance of prolactin secretion.

Bromocriptine↗

Short-term management of macroprolactinomas with a new injectable form of bromocriptine.

Three cases (2 men, 1 woman) of expansive macroprolactinoma treated with a single 50-mg intramuscular dose of a new form of injectable, long-acting bromocriptine are presented. Clinical manifestations included visual disturbances (2 cases), headache (1 case), and hypogonadism (3 cases). Laboratory tests demonstrated high basal serum prolactin (PRL) levels and evidence of involvement of other anterior pituitary hormones in all cases. Treatment was followed by marked improvement of symptoms paralleled by a sharp decrease of serum PRL levels, which normalized in 1 case. Some other anterior pituitary functions also improved. Computed tomography scan revealed shrinkage of the tumor in all cases. There were no local or serious systemic side effects. These initial findings suggest that long-acting injectable bromocriptine has a place in the initial treatment of macroprolactinomas, especially for those with neurological and/or visual manifestations. It can also be used to select patients for surgery, in the cases where clinical and radiological improvement could not be obtained. The effects of long-term use remain to be established by further studies.

Adult↗

Cerebrospinal fluid rhinorrhea occurring in long-term bromocriptine treatment for macroprolactinomas.

Two patients harboring invasive macroprolactinomas, on treatment with bromocriptine, developed cerebrospinal fluid rhinorrhea 16 and 17 months after the beginning of the medical therapy. Neither patient had previously been submitted to surgery or radiotherapy. The fistulae were surgically corrected. Cerebrospinal fluid leakage is a well-documented complication of pituitary tumors, mainly after surgery and/or radiotherapy, but the reports of its occurrence after primary treatment with bromocriptine are rare. Therefore, the possibility of this complication must be considered, especially in patients with invasive macroprolactinomas.

Adult↗

Bromocriptine in the treatment of carcinoma of the cervix: a phase II trial.

Twenty patients with advanced carcinoma of the uterine cervix were treated for at least 3 months with 5 mg bromocriptine daily. No remissions were found (95% confidence limits, 0-17%), neither among normo- nor among hyperprolactinemic patients. Twelve had stable disease for 2-9 months with a median of 3 months. The results of this study does not support the hypothesis that bromocriptine possesses any antitumor effect in cancer of the uterine cervix.

Adult↗

Effect of acute administration of bromocriptine on isoproterenol- and angiotensin II-induced water intake in estrogen-treated rats.

Chronic administration of an estrogenic agent is well known to attenuate the drinking response of rats to treatment with a variety of dipsogenic agents, and to increase plasma concentration of prolactin. Treatment with prolactin is also known to reduce the drinking response to administration of the dipsogenic agent, isoproterenol. Hence, a possibility existed that the antidipsogenic effect of chronic treatment with estrogen was mediated by an increased plasma prolactin concentration. Since bromocriptine, a dopaminergic agonist, is known to reduce plasma prolactin concentration in estrogen-treated rats, it was administered (1.0 mg/kg, IP) 15 min prior to treatment with either isoproterenol (25 micrograms/kg, SC) or angiotensin II (200 micrograms/kg, SC). The results suggest that the antidipsogenic effect of chronic treatment of rats with estradiol benzoate (30.4 and 45.7 micrograms/kg/day) can be reversed, at least partially, by acute administration of bromocriptine.

Angiotensin II↗

Bromocriptine, a D2 receptor agonist, lowers the threshold for rewarding brain stimulation.

Drug-induced lowering of brain stimulation reward threshold can serve as a model for the pharmacological activation of reward pathways. Here, the effects of bromocriptine, a direct D2 dopamine receptor agonist, on reward thresholds were investigated. Bromocriptine administration resulted in the significant lowering of threshold levels in all test animals, suggesting that this agent can activate the same reward processes as do abused substances such as cocaine and morphine.

Animals↗

Bromocriptine associated with postpartum hypertension, seizures, and pituitary hemorrhage.

Bromocriptine, an ergot alkaloid dopamine agonist, is a recent common treatment for suppression of lactation in postpartum women. A case is presented of a postpartum woman prescribed bromocriptine for suppression of lactation who developed hypertension, headaches, blurry vision, seizures, and pituitary hemorrhage. Differential diagnosis and a literature review are considered.

Adult↗

Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation.

Ten chronic schizophrenic patients were given bromocriptine in doses increasing from 1.25 to 5 mg over 6 days (the low-dose therapy) and then up to 40 mg over 15 days (the high-dose therapy). Psychopathological status was assessed using the Brief Psychiatric Rating Scale, twice daily the first 6 days, and every 2 days thereafter. The prolactin (PRL) response to haloperidol stimulation (1 mg i.v.) was measured in five cases before and 3 days after the end of high-dose therapy, and in one patient before and 3 days after the end of low-dose therapy. Electroencephalographic sleep studies were carried out before therapy and every 2 nights during low-dose therapy in five patients, and in two cases during high-dose therapy. Bromocriptine therapy modified neither clinical symptomatology nor sleep patterns. The PRL response to haloperidol after therapy was markedly lower than that before therapy in the five patients treated with high doses, and markedly higher in the single patient tested who was treated only with low-dose therapy.

Adult↗

Bromocriptine-unresponsive prolactin macroadenoma in a prepubertal female.

Macroprolactinomas occur rarely in prepubertal children. A prepubertal 11 10/12-year-old female with a macroprolactinoma presented with a diagnosis of anorexia nervosa. Findings included severe headaches, anorexia, weight loss, and growth failure. The initial serum prolactin level was 2,916 ng/ml. This value fell after beginning treatment with bromocriptine, but later rose despite a doubling of the dose. Transsphenoidal surgical resection was performed and postoperative radiation given. The use of bromocriptine, surgical resection, and radiation therapy in the treatment of macroprolactinomas are discussed.

Adenoma↗